These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29043987)

  • 61. The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine.
    Miltiades P; Lamprianidou E; Vassilakopoulos TP; Papageorgiou SG; Galanopoulos AG; Kontos CK; Adamopoulos PG; Nakou E; Vakalopoulou S; Garypidou V; Papaioannou M; Hatjiharissi E; Papadaki HA; Spanoudakis E; Pappa V; Scorilas A; Tsatalas C; Kotsianidis I;
    Clin Cancer Res; 2016 Apr; 22(8):1958-68. PubMed ID: 26700206
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
    Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
    Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
    [TBL] [Abstract][Full Text] [Related]  

  • 63. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Flotho C; Sommer S; Lübbert M
    Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Has introduction of azacytidine in everyday clinical practice improved survival in late-stage Myelodysplastic syndrome? A single center experience.
    Papoutselis M; Douvali E; Papadopoulos V; Spanoudakis E; Margaritis D; Tsatalas C; Kotsianidis I
    Leuk Res; 2014 Feb; 38(2):161-5. PubMed ID: 24239174
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Myelofibrosis as the initial presentation of donor-derived myelodysplastic syndrome/AML: failure of a lasting response to a second allogeneic transplant from the original donor.
    Cutting RJ; Welch E; Channer J; Ezaydi Y; Talley P; Reilly JT; Snowden JA
    Bone Marrow Transplant; 2008 Nov; 42(9):631-3. PubMed ID: 18695662
    [No Abstract]   [Full Text] [Related]  

  • 66. Myelodysplasia, megakaryocytes, and methylation.
    Steensma DP
    Leuk Res; 2004 Aug; 28(8):775-6. PubMed ID: 15203274
    [No Abstract]   [Full Text] [Related]  

  • 67. [Successful treatment with azacitidine for a patient with relapsed myelodysplastic syndrome after cord blood transplantation].
    Ueda S; Miyakoshi S; Chizuka A; Kojima R; Ogasawara T; Miyamoto K
    Rinsho Ketsueki; 2013 Dec; 54(12):2177-81. PubMed ID: 24452149
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.
    Villela L; Anders V; Bolaños-Meade J
    Anticancer Drugs; 2010 Apr; 21(4):469. PubMed ID: 20216343
    [No Abstract]   [Full Text] [Related]  

  • 69. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
    Demakos EP; Linebaugh JA
    Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Damaj G; Mohty M; Robin M; Michallet M; Chevallier P; Beguin Y; Nguyen S; Bories P; Blaise D; Maillard N; Rubio MT; Fegueux N; Cornillon J; Clavert A; Huynh A; Adès L; Thiébaut-Bertrand A; Hermine O; Vigouroux S; Fenaux P; Duhamel A; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1349-55. PubMed ID: 24838178
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Multifaceted modes of action of azacytidine: a riddle wrapped up in an enigma.
    Lamprianidou E; Zoulia E; Bernard E; Kordella C; Papoutselis M; Bezirgiannidou Z; Vrachiolias G; Papaemmanuil E; Kotsianidis I
    Leuk Lymphoma; 2019 Dec; 60(13):3277-3281. PubMed ID: 31185765
    [No Abstract]   [Full Text] [Related]  

  • 72. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
    Tomonaga M; Kamae I
    Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.
    Klimek VM; Dolezal EK; Tees MT; Devlin SM; Stein K; Romero A; Nimer SD
    Leuk Res; 2012 Sep; 36(9):1093-7. PubMed ID: 22608310
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
    Steensma DP
    Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group.
    Cseh A; Niemeyer CM; Yoshimi A; Dworzak M; Hasle H; van den Heuvel-Eibrink MM; Locatelli F; Masetti R; Schmugge M; Groß-Wieltsch U; Candás A; Kulozik AE; Olcay L; Suttorp M; Furlan I; Strahm B; Flotho C
    Blood; 2015 Apr; 125(14):2311-3. PubMed ID: 25838281
    [No Abstract]   [Full Text] [Related]  

  • 76. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
    Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Myelodysplastic syndromes: emerging therapies, survival, and alternative outcomes.
    Scott BL
    Manag Care; 2009 Nov; 18(11 Suppl 9):4-12; discussion 13-4. PubMed ID: 20085111
    [No Abstract]   [Full Text] [Related]  

  • 78. Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes.
    Chou WC; Yeh SP; Hsiao LT; Lin SF; Chen YC; Chen TY; Laille E; Galettis A; Dong Q; Songer S; Beach CL
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e430-e439. PubMed ID: 28124500
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.
    Radsak M; Platzbecker U; Schmidt CS; Hofmann WK; Nolte F
    Eur J Haematol; 2017 Aug; 99(2):112-118. PubMed ID: 28321924
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine.
    Infante MS; Muñoz C; Heras C; Foncillas MA; González I; Lucea I; Echavarria E; Aramendi T; Hernández JA
    Eur J Dermatol; 2015; 25(6):622-3. PubMed ID: 26552844
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.